Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial

The Lancet

Volumn 382, Issue 9886, 2013, Pages 50-56

  Tsai, Joy N ^a   Uihlein, Alexander V ^a   Lee, Hang ^a   Kumbhani, Ruchit ^a   Siwila Sackman, Erica ^a   McKay, Elizabeth A ^a   Burnett Bowie, Sherri Ann M ^a   Neer, Robert M ^a   Leder, Benjamin Z ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; OSTEOCALCIN; PARATHYROID HORMONE[1-34];

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BREAST CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; HUMAN; HYPERGLYCEMIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT;

EID: 84879887680     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60856-9     Document Type: Article

References (22)

1. DM Reid, D Hosking, D Kendler et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS- international Clin Drug Invest 26 2006 63 74
2. UA Liberman, SR Weiss, J Bröll et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1995 1437 1443
3. S Adami, D Felsenberg, C Christiansen et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months Bone 34 2004 881 889
4. IR Reid, JP Brown, P Burckhardt et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 2002 653 661
5. RM Neer, CD Arnaud, JR Zanchetta et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
6. SR Cummings, J San Martin, MR McClung et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
7. DL Lacey, E Timms, HL Tan et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
8. JE Fisher, GA Rodan, AA Reszka In vivo effects of bisphosphonates on the osteoclast mevalonate pathway Endocrinology 141 2000 4793 4796
9. JS Finkelstein, A Hayes, JL Hunzelman, JJ Wyland, H Lee, RM Neer The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 2003 1216 1226
10. DM Black, SL Greenspan, KE Ensrud et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
11. JS Finkelstein, JJ Wyland, H Lee, RM Neer Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis J Clin Endocrinol Metab 95 2010 1838 1845
12. F Cosman, EF Eriksen, C Recknor et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis J Bone Miner Res 26 2011 503 511
13. PJ Kostenuik, C Capparelli, S Morony et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats Endocrinology 142 2001 4295 4304
14. DD Pierroz, N Bonnet, PA Baldock et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL J Biol Chem 285 2010 28164 28173
15. R Samadfam, Q Xia, D Goltzman Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice J Bone Miner Res 22 2007 55 63
16. DM Black, M Steinbuch, L Palermo et al. An assessment tool for predicting fracture risk in postmenopausal women Osteoporos Int 12 2001 519 528
17. C Muschitz, R Kocijan, A Fahrleitner-Pammer, S Lung, H Resch Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density J Bone Miner Res 28 2013 196 205
18. JS Finkelstein, BZ Leder, SM Burnett et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men J Clin Endocrinol Metab 91 2006 2882 2887
19. PD Delmas, P Vergnaud, ME Arlot, P Pastoureau, PJ Meunier, MHL Nilssen The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16 1995 603 610
20. YL Ma, Q Zeng, DW Donley et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis J Bone Miner Res 21 2006 855 864
21. P Chen, PD Miller, PD Delmas, DA Misurski, JH Krege Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis J Bone Miner Res 21 2006 1785 1790
22. M Austin, YC Yang, E Vittinghoff et al. FREEDOM Trial. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures J Bone Miner Res 27 2012 687 693